http://orcid.org/0000-0003-3292-2045
References
- Blencowe H, Cousens S, Oestergaard MZ, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet. 2012;379(9832):2162–2172.
- Hamilton BE, Martin JA, Osterman MJK, et al. Births: final data for 2014. Natl Vital Stat Rep. 2015;64(12):1–64.
- Moore T, Hennessy EM, Myles J, et al. Neurological and developmental outcome in extremely preterm children born in England in 1995 and 2006: the EPICure studies. BMJ. 2012;345:e7961.
- Nelson KB, Grether JK. Can magnesium sulfate reduce the risk of cerebral palsy in very low birthweight infants? Obs Gyn Surv. 1995;50(8):573–575.
- Crowther CA, Hiller JE, Doyle LW, et al. Effect of magnesium sulfate given for neuroprotection before preterm birth: a randomized controlled trial. JAMA. 2003;290(20):2669–2676.
- Marret S, Marpeau L, Zupan-Simunek V, et al. Magnesium sulphate given before very-preterm birth to protect infant brain: the randomised controlled PREMAG trial. BJOG. 2007;114(3):310–318.
- Rouse DJ, Hirtz DG, Thom E, et al. A randomized, controlled trial of magnesium sulfate for the prevention of cerebral palsy. N Engl J Med. 2008;359(9):895–905.
- American College of Obstetricians & Gynecologists. Committee Opinion No. 455. Magnesium sulfate before anticipated preterm birth for neuroprotection. Obstet Gynecol. 2010;115(3):669–671.
- Crowther CA, Middleton PF, Voysey M, et al. Assessing the neuroprotective benefits for babies of antenatal magnesium sulphate: an individual participant data meta-analysis. PLOS Med. 2017;14(10):e1002398.
- Turitz AL, Too GT, Gyamfi-Bannerman C. Proximity of magnesium exposure to delivery and neonatal outcomes. Am J Obstet Gynecol. 2016;215(4):508.e1–508.e6.
- Sims EJ, Vermillion ST, Soper DE. Preterm premature rupture of the membranes is associated with a reduction in neonatal respiratory distress syndrome. Am J Obstet Gynecol. 2002;187(2):268–272.
- Chang E. Preterm birth and the role of neuroprotection. BMJ. 2015;350:g6661.
- Lecuyer M, Rubio M, Chollat C, et al. Experimental and clinical evidence of differential effects of magnesium sulfate on neuroprotection and angiogenesis in the fetal brain. Pharmacol Res Perspect. 2017;5(4):1–20.
- Dribben WH, Creeley CE, Wang HH, et al. High dose magnesium sulfate exposure induces apoptotic cell death in the developing neonatal mouse brain. Neonatology. 2009;96(1):23–32.
- USFDA. FDA drug safety communication: FDA recommends against prolonged use of magnesium sulfate to stop pre-term labor due to bone changes in exposed babies; 2013.
- Mittendorf R, Covert R, Boman J, et al. Is tocolytic magnesium sulphate associated with increased total paediatric mortality? Lancet. 1997;350(9090):1517–1518.
- Mittendorf R, Dambrosia J, Dammann O, et al. Association between maternal serum ionized magnesium levels at delivery and neonatal intraventricular hemorrhage. J Pediatr. 2002;140(5):540–546.
- Mittendorf R, Dammann O, Lee KS. Brain lesions in newborns exposed to high-dose magnesium sulfate during preterm labor. J Perinatol. 2006;26(1):57–63.
- Grimes DA, Nanda K. Magnesium sulfate tocolysis: time to quit. Obstet Gynecol. 2006;108(4):986–989.
- McPherson JA, Rouse DJ, Grobman WA, et al. Association of duration of neuroprotective magnesium sulfate infusion with neonatal and maternal outcomes. Obstet Gynecol. 2014;124(4):749–755.